Elanco Raises Full-Year Outlook on Strong Q2 Performance — Elanco Animal Health Incorporated

Event summary

Elanco reported Q2 2026 revenue of $1.37B, up 10% YoY (8% organic constant currency growth).
Adjusted EBITDA rose 21% to $288M, with an adjusted EBITDA margin of 21.2%.
The company raised its full-year revenue guidance to $5.09B–$5.14B (up from $5.01B–$5.09B).
Zenrelia and Credelio Quattro drove market share gains, with Zenrelia achieving blockbuster status.
Net leverage ratio improved to 3.1x adjusted EBITDA, ahead of expectations.

The big picture

Elanco's strong Q2 results reflect its strategic focus on innovation and market share expansion in both pet health and farm animal segments. The company's ability to raise full-year guidance underscores its leadership position in the animal health industry, where demand for innovative therapies remains robust. The improved net leverage ratio also signals progress toward greater financial flexibility.

What we're watching

Innovation Momentum: Whether Elanco can sustain the strong performance of Zenrelia and Credelio Quattro in key markets.
Debt Reduction Progress: The pace at which Elanco reduces its net leverage ratio below 3x by next year.
Operational Efficiency: How the company's Elanco Ascend productivity initiatives will impact long-term cost savings.